See more : Gujarat Lease Financing Limited (GLFL.NS) Income Statement Analysis – Financial Results
Complete financial analysis of Allena Pharmaceuticals, Inc. (ALNA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Allena Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- CyanConnode Holdings plc (CYAN.L) Income Statement Analysis – Financial Results
- AEGIS LOGISTICS LIMITED (AEGISLOG.NS) Income Statement Analysis – Financial Results
- Actic Group AB (publ) (ATIC.ST) Income Statement Analysis – Financial Results
- NIO Inc. (0A1K.L) Income Statement Analysis – Financial Results
- Yunkang Group Limited (2325.HK) Income Statement Analysis – Financial Results
Allena Pharmaceuticals, Inc. (ALNA)
About Allena Pharmaceuticals, Inc.
Allena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. Its lead product candidate is ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and gout in the setting of advanced chronic kidney disease. The company was incorporated in 2011 and is headquartered in Newton, Massachusetts.
Metric | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
---|---|---|---|---|---|---|---|
Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Research & Development | 20.38M | 20.38M | 37.24M | 26.38M | 15.52M | 20.10M | 11.54M |
General & Administrative | 11.60M | 11.60M | 9.68M | 8.64M | 5.43M | 4.08M | 2.37M |
Selling & Marketing | 0.00 | 0.00 | 0.00 | 576.00K | 0.00 | 0.00 | 0.00 |
SG&A | 11.60M | 11.60M | 9.68M | 9.22M | 5.43M | 4.08M | 2.37M |
Other Expenses | 0.00 | 0.00 | 605.00K | 0.00 | 0.00 | 0.00 | 0.00 |
Operating Expenses | 31.99M | 31.99M | 46.92M | 35.59M | 20.95M | 24.19M | 13.91M |
Cost & Expenses | 31.99M | 31.99M | 46.92M | 35.59M | 20.95M | 24.19M | 13.91M |
Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Interest Expense | 510.00K | -510.00K | 270.00K | 575.00K | -443.00K | 0.00 | 0.00 |
Depreciation & Amortization | 363.00K | 166.00K | 163.00K | 78.00K | 73.00K | 46.00K | 98.00K |
EBITDA | -31.97M | -32.68M | -47.18M | -35.57M | -21.58M | -24.46M | -14.15M |
EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Operating Income | -32.34M | -31.99M | -46.92M | -35.59M | -20.95M | -24.19M | -13.91M |
Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Total Other Income/Expenses | -510.00K | -859.00K | 0.00 | -55.00K | -700.00K | -321.00K | -342.00K |
Income Before Tax | -32.85M | -32.85M | -47.34M | -35.65M | -21.65M | -24.51M | -14.25M |
Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Income Tax Expense | 510.00K | -859.00K | -419.00K | -55.00K | -700.00K | -321.00K | -342.00K |
Net Income | -33.36M | -32.85M | -47.34M | -35.65M | -21.65M | -24.51M | -14.25M |
Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
EPS | -1.03 | -1.01 | -2.13 | -1.72 | -4.79 | -1.60 | -0.93 |
EPS Diluted | -1.03 | -1.01 | -2.13 | -1.72 | -4.79 | -1.60 | -0.93 |
Weighted Avg Shares Out | 32.51M | 32.51M | 22.18M | 20.74M | 4.52M | 15.28M | 15.29M |
Weighted Avg Shares Out (Dil) | 32.51M | 32.51M | 22.18M | 20.74M | 4.52M | 15.28M | 15.29M |
Allena Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
ALNA Stock Fell 35.04%: Why It Happened
Allena Pharmaceuticals Announces $28 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
Allena Pharmaceuticals, Inc. to Present at the Ladenburg Thalmann 2021 Virtual Healthcare Conference
Allena Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Allena Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Allena Pharmaceuticals to Host Key Opinion Leader Webinar Focused on ALLN-346 for the Treatment of Gout in Patients with Chronic Kidney Disease
Top Penny Stocks For Your May Watchlist? Check These 5 Out
Moving Average Crossover Alert: Allena Pharmaceuticals (ALNA)
Allena Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Source: https://incomestatements.info
Category: Stock Reports